^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Anaplastic Astrocytoma

    Related cancers:
    5d
    Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy (clinicaltrials.gov)
    P1, N=20, Recruiting, Mayo Clinic | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    IDH wild-type
    7d
    MET fusions and splicing variants in glioma: a landscape integrating clinical, pathological, and survival features. (PubMed, J Pathol Clin Res)
    ZM fusion was associated with a worse prognosis in both astrocytoma (OS p < 0.001, PFS p < 0.001) and glioblastoma (OS, p = 0.252; PFS, p = 0.010) patients. We highlight the utmost relevance of ZM fusion as an adverse prognostic factor in astrocytoma (11/382, 2.88%) and glioblastoma grade 4 (11/401, 2.74%) patients and suggest that the grading of these tumors should be refined.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)
    |
    MET expression
    |
    TruSight Tumor 170 Assay
    8d
    HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM (clinicaltrials.gov)
    P1/2, N=62, Recruiting, The Methodist Hospital Research Institute | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    ProstAtak (aglatimagene besadenovec) • valacyclovir
    10d
    Expanding the molecular grading criteria in IDH-mutant astrocytoma. (PubMed, Neuro Oncol)
    The presence of CDK4, CCND2, PDGFRA, PIK3R1, MYCN, and EGFR alterations result in an intermediate patient survival in IDH-mutant astrocytoma. Adding these molecular alterations should be considered in future diagnostic classification systems to improve stratification of high-risk patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TERT (Telomerase Reverse Transcriptase) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • CCND2 (Cyclin D2)
    |
    EGFR mutation • PIK3CA mutation • EGFR amplification • CDKN2A deletion • MYCN amplification • PDGFRA mutation
    14d
    RagC and Map4K3 deficiency in high-grade gliomas drives proliferation and modulates mTORC1-dependent cellular functions. (PubMed, J Neuropathol Exp Neurol)
    In contrast, RagC-deficient U87 cells showed increased senescence but no autophagy induction. These data show that losses of RagC and Map4K3 in malignant gliomas have proliferation-inducing effects and differentially modulate key mTOR signaling-dependent cellular mechanisms.
    Journal
    |
    TFEB (Transcription Factor EB 2) • RRAGD (Ras related GTP binding)
    22d
    Clinical and genetic determinants of glioblastoma survival: a retrospective study. (PubMed, Front Mol Neurosci)
    A significant finding was the strong association between extent of resection, tumor proximity to the ventricular system and survival: patients with tumors closer to the ventricles had significantly shorter survival, highlighting the critical role of spatial tumor characteristics in glioblastoma outcomes. These results suggest that integrating clinical, genetic and spatial tumor data into personalized treatment approaches could improve prognosis.
    Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    TP53 mutation • EGFR mutation
    26d
    Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas (clinicaltrials.gov)
    P1/2, N=33, Not yet recruiting, Mayo Clinic
    New P1/2 trial
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH wild-type
    |
    Zynyz (retifanlimab-dlwr)
    26d
    Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion (clinicaltrials.gov)
    P1, N=15, Recruiting, Nationwide Children's Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 fusion
    |
    carboplatin • Lorbrena (lorlatinib) • cyclophosphamide
    29d
    UNITED-4: UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4 (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Sunnybrook Health Sciences Centre
    New trial
    |
    IDH wild-type
    29d
    High-grade gliomas and Lynch syndrome: A retrospective descriptive study with a literature review. (PubMed, Neurooncol Pract)
    We propose with a review of case in the literature an algorithm for investigating LS upon discovering a GBM. These exploratory results need to be confirmed by a larger cohort.
    Retrospective data • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation • PTEN mutation
    1m
    Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse (clinicaltrials.gov)
    P2, N=19, Terminated, Exelixis | Completed --> Terminated; Enrollment in this study was terminated for business development reasons before completing one third of the expected subject population, no formal statistical testing was performed.
    Trial termination
    |
    Cabometyx (cabozantinib tablet)
    1m
    A Case of IDH-Mutant Astrocytoma Harboring an IDH2 R172_H173delinsSN Variant. (PubMed, Neuropathology)
    He received adjuvant concurrent radiation and temozolomide...We present a case of IDH-mutant astrocytoma with a somewhat atypical molecular presentation, including a previously uncharacterized IDH2 mutation, retained ATRX expression, and lack of MGMT promoter hypermethylation. Though it has not been biochemically or functionally validated, tumor methylation profiling is supportive of this previously uncharacterized IDH2 variant as tumorigenic.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ATRX (ATRX Chromatin Remodeler)
    |
    IDH2 mutation • IDH1 R132 • IDH2 R172
    |
    temozolomide